Global Computer-aided Drug Discovery Market Anticipated to Garner a Revenue of $7,504.7 Million and Rise at a Noteworthy CAGR of 11.48% over the 2022-2030 Timeframe [240-Pages]

Strategist Michael Antonelli joins Jared Blikre to break down the Fed decision and more at 2 P.M. ET Wednesday.
The global computer-aided drug discovery market is expected to see striking growth by 2030, due to the growing utilization of artificial intelligence in drug discovery. The North America region is expected to hold the largest share of the market.
NEW YORK, June 21, 2022 /PRNewswire/ — Research Dive has added a new report to its offering titled, ‘Computer-aided Drug Discovery Market by Type (Structure-Based Drug Design (SBDD), Ligand-based Drug Design (LBDD), and Sequence-based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, and Others), End-user (Pharmaceutical Companies, Biotechnology Companies, and Research Laboratories) and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022–2030.’
According to the report published by Research Dive, the global computer-aided drug discovery market is anticipated to generate a revenue of $7,504.7 million and grow at a healthy CAGR of 11.48% during the estimated period from 2022 to 2030.
Access an Exclusive PDF Sample of the Computer-aided Drug Discovery Market (Including Tables, TOC, and Figures)
Dynamics of the Computer-aided Drug Discovery Market
The increasing usage of artificial intelligence in drug discovery for chemical synthesis, polypharmacology, drug screening, and studying the three-dimensional structure of molecules, is expected to fortify the growth of the computer-aided drug discovery market over the analysis period. Besides, the increasing demand for high-speed drug development for various chronic development like cancer is further expected to bolster the growth of the market during the forecast period. Moreover, the increasing technological advancements in the field of computer-aided drug discovery and growing research activities to provide accurate results in less time are the factors expected to create expansive growth opportunities for the market. However, the lack of skilled professionals in this field may hinder the growth of the market over the estimated timeframe.
Covid-19 Impact on the Computer-aided Drug Discovery Market
Though the rise of the novel coronavirus has devastated several other industries, the computer-aided drug discovery market has experienced a positive impact during the pandemic period. This is mainly due to the increasing R&D activities among scientists, researchers, and biopharmaceutical companies to control the spread of the deadly virus. This has skyrocketed drug discovery activities all across the globe. In addition, the huge investment made by leading market players for technological development in research and development activities has inclined the growth of the market during the period of crisis.
Specific Requirements on Post COVID-19 Impact on Computer-aided Drug Discovery Market? Connect with an Expert Analyst
Segments of the Computer-aided Drug Discovery Market
The report has divided the market into different segments based on type, therapeutic area, end-user, and region.
By type, the structure-based drug design sub-segment is expected to be productive and is projected to generate a revenue of $2,471.3 million during the analysis period. The increasing demand for new drugs for various diseases and increasing technological advancements in drug discovery are expected to boost the growth of the market sub-segment over the estimated timeframe.
By therapeutic area, the oncology sub-segment is predicted to be the most profitable and is expected to generate a revenue of $1,826.3 million during the forecast period. The increasing demand for cost-effective, successful, and efficient cancer drugs for the treatment of different types of cancer is expected to uplift the growth of the market sub-segment throughout the analysis period.
By end-user, the pharmaceutical companies sub-segment is expected to most lucrative and is projected to garner a revenue of $3,018.9 million over the estimated timeframe. The increasing need for applying different approaches to identify chemical compounds beneficial for human use is expected to augment the growth of the market sub-segment during the forecast period.
By region, the North America region of the computer-aided drug discovery market is expected to hold the maximum share of the market and is predicted to generate a revenue of $2,514.1 million during the estimated period and grow at a healthy CAGR of 10.83% during the analysis period. The increasing number of cancer cases in this region and growing research activities in institutes and hospitals using computer-aided drug discovery in the field of cancer is expected to drive the regional growth of the market over the analysis period.
Request for Computer-aided Drug Discovery Market Research Report Customization and Avail Amazing Discount
Key Players of the Computer-aided Drug Discovery Market
The major players of the computer-aided drug discovery market include
Aris Pharmaceuticals, Inc
Charles River Laboratories
Aragon Life Sciences Pvt. Ltd.
Bayer AG
Schrödinger, Inc.
AstraZeneca
Bioduro-Sundia
Albany Molecular Research Inc. (AMRI)
BOCSCI Inc
These players are widely working on the development of new strategies such as product development, mergers, collaborations, mergers, and acquisitions to procure a leading position in the global industry.
For instance, in April 2022, Iktos, a leading drug discovery company specializing in the development of AI solutions applied to chemical research, collaborated with Teijin Pharma, a renowned company that provides comprehensive healthcare services to improve the quality of life. With this collaboration, the companies will focus on the incorporation of AI technology to enhance the speed of the drug design process for small molecule drug discovery.
Further, the report also summarizes other important aspects such as product portfolio, the financial performance of the key players, SWOT analysis, and the latest strategy development.
More about Computer-aided Drug Discovery Market:
Computer-aided Drug Discovery: A Quick Look at its Types and Examples
What is the need for Computer-aided Drug Discovery in Today’s World?
Global Computer-aided Drug Discovery Market to Rise at a CAGR of 11.48% and Surpass $7,504.7 Million by 2030, Owing to Increasing Investments in Research Activities for Drug Development
Related Trending Article Links:
The global medical waste management market was valued at $9,727.24 million in 2020 and is projected to reach $16,395.80 million by 2028: Grab an PDF Sample
The global life science analytics software market is anticipated to garner $13,375.8 million in the 2021–2028 period: Grab an PDF Sample
The global patient centric healthcare app market is predicted to garner $3, 85,767.5 million in the 2020–2027 timeframe: Grab an PDF Sample
About Research Dive
Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With an unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.
Contact:
Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York NY 10005
(P) +91-(788)-802-9103 (India)
+1-(917)-444-1262 (US)
Toll Free: 1-888-961-4454
E-mail: support@researchdive.com
Website: https://www.researchdive.com
Blog: https://www.researchdive.com/blog/
LinkedIn: https://www.linkedin.com/company/research-dive/
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive-1385542314927521
Logo : https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-computer-aided-drug-discovery-market-anticipated-to-garner-a-revenue-of-7-504-7-million-and-rise-at-a-noteworthy-cagr-of-11-48-over-the-20222030-timeframe-240-pages–research-dive-301571797.html
SOURCE Research Dive
NFP, a leading property and casualty broker, benefits consultant, wealth manager and retirement advisor, today announced the hiring of John Stewart to serve as senior vice president, surety leader, in Canada. In this role Stewart will leverage his underwriting expertise with multinational companies to lead strategic surety business development in Canada and build a national surety team to service clients' contract and commercial bonding needs. He will report to Guy Jolicoeur, managing director,
The government health-insurance program for seniors could have saved as much as $3.6 billion over one year if it had bought generic drugs from the pharmacy, Harvard Medical School researchers estimate.
(Reuters) -The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.
Jab maker Moderna plans to open first vaccine factory in Britain, as it hailed the UK’s “world-class life sciences and research community” which came to the fore during the pandemic.
U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. ; shares in Ionis were up 5.1% on Tuesday. The rare disease can cause nerve damage and motor disability and affects about 40,000 people worldwide, the companies said. They also said they plan to see
Top pharmaceutical company Eli Lilly's (NYSE: LLY) diabetes division achieved a key milestone with the approval of Mounjaro in May for type 2 diabetes. This is a turnaround from earlier this year when the prospects of key immunology blockbuster Olumiant were dampened by Food and Drug Administration (FDA) concerns over its safety. Lilly's strengthening outlook for its immunology treatments has the potential to shore up future revenue growth.
The Chester County company is working with the India-based developer of Covaxin to bring the Covid-19 vaccine to North America.
Is COVID over in the minds of Americans?
Researchers describe findings as ‘extremely exciting’
Virtual offices are the dream for many tech CEOs, but working in the metaverse still has a few kinks.
The inability to stand on one leg for 10 seconds after the age of 50 could indicate an early death is on the horizon, new research suggests.
“The United States is now the first country in the world to offer safe and effective COVID-19 vaccines for children as young as 6 months old,” President Biden said Tuesday at the White House.
These healthy thirst-quenchers are a triple threat: refreshing, tasty, and hydrating.
StarMed Healthcare announced it will start administering the newly approved COVID-19 vaccines to children as young as 6 months old.
The likely end of federal abortion rights won’t just make it more difficult for women to get an abortion. It’s also almost certain to make it more difficult to train medical professionals on abortion procedures — a skill that doctors and others who take care of women’s health consider essential. The prospect raises “a huge […]
From early in the pandemic, it quickly became clear that certain people would feel COVID-19′s wrath to a much higher degree than other people.
SEOUL (Reuters) -South Korea on Wednesday confirmed its first case of monkeypox virus and pledged to strengthen monitoring and response systems as it raised the alert level to "caution" for the infectious disease. A Korean citizen, who is receiving treatment at the Incheon Medical Center after showing symptoms while entering the country from Germany on Tuesday afternoon, has tested positive, the Korea Disease Control and Prevention Agency (KDCA) said. The agency raised the alert level for the infectious disease to "caution", the second of the country's four levels, upon confirmation of the virus case.
Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted. COVAX, the World Health Organization-led scheme, wants between 400 and 600 million fewer vaccines doses than initially contracted from six pharmaceutical companies, according to internal documents seen by Reuters. While at first the initiative struggled for shots as wealthy nations snapped up limited supply, donations from those same countries later in 2021, as well as improved output from manufacturers – alongside delivery challenges and vaccine hesitancy in a number of countries – has led to a glut of vaccine in 2022.
Medicare would save billions of dollars if it purchased generic drugs at prices similar to those offered by a pharmaceutical company founded by billionaire entrepreneur Marc Cuban, according to a new study published in the journal Annals of Internal Medicine. Cuban launched the firm – the Mark Cuban Cost Plus Drug Company – at the beginning of the year to provide more than 100 generic drugs without the exorbitant profits and middlemen charges that are typically found in the market. “Our approach
WASHINGTON (Reuters) -General Motors Co, Ford Motor Co and Chrysler parent Stellantis NV said on Tuesday they are making masking optional for workers at all U.S. facilities. In mid-May, the Detroit Three automakers and the United Auto Workers — which have a COVID-19 joint task force — reinstated a requirement that employees wear masks in southeastern Michigan, which was dealing with high COVID-19 rates. The task force said on Tuesday it "strongly recommends masking" if a facility is in a high-risk county as identified by the Center for Disease Control (CDC) but that they will not be required.

source

Related Articles